Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
Iain Crossingham(East Lancashire Hospitals NHS Trust), Timothy Hinks(University of Oxford), Sanjay Ramakrishnan(Oxford BioMedica (United Kingdom)), Anastasia Fries(Nuffield Orthopaedic Centre), Gareth Hynes(University of Oxford), Farhat Yasmin(Kettering General Hospital), Adnan Chaudhry(East Lancashire Hospitals NHS Trust), Sally Turner(Royal Blackburn Teaching Hospital), Matthew Gowell(New College)
Cited by 43
Related Papers
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
|Thorax|2021|169
Survival analysis of patients on maintenance hemodialysis
|Indian Journal of Nephrology|2014|100
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
|The Lancet Respiratory Medicine|2024|98